Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26797587 | 0.87 | MAPKAPK2 (0.39) | MAPKAPK2ATRSTK17BSTK17ALCK | |
| SCHEMBL28816599 | 0.82 | MAPKAPK2 (0.46) | MAPKAPK2ATRSTK17BSTK17ATRPA1 | |
| SCHEMBL29844553 | 0.82 | MAPKAPK2 (0.46) | MAPKAPK2ATRSTK17BSTK17ATRPA1 | |
| SCHEMBL31132878 | 0.81 | CCR4 (0.46) | MAPKAPK2ATRSTK17BSTK17ASYK | |
| SCHEMBL27793321 | 0.78 | ATR (0.43) | ATRSTK17BSTK17ALCKNAMPT | |
| SCHEMBL29537838 | 0.78 | ATR (0.44) | MAPKAPK2ATRSTK17BSTK17ATRPA1 | |
| SCHEMBL16915789 | 0.78 | GRM5 (0.34) | MAPKAPK2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2885204 | 0.78 | MAPKAPK2 (0.41) | MAPKAPK2ATRSTK17BSTK17ALCK | |
| SCHEMBL29277697 | 0.77 | ATR (0.49) | MAPKAPK2ATRSTK17BSTK17ATRPA1 | |
| SCHEMBL31093832 | 0.77 | ATR (0.46) | MAPKAPK2ATRSTK17BSTK17ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401259-B2 | 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 | PTPN5, PTPN1, PTPN2 | MAPKAPK2 387/4885ATR 1351/4885STK17B 330/4885 |
| US-20220348553-A1 | 1-PYRIDAZIN-/TRIAZIN-3-YL-PIPER(-AZINE)/IDINE/PYROLIDINE DERIVATIVES AND COMPOSITIONS THEREOF FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN5, PTPN1, PTPN2 | MAPKAPK2 387/4885ATR 1351/4885STK17B 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.